Taxanes for the Treatment of Metastatic Breast Cancer
Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances delivery o...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486789/ |
| id |
pubmed-3486789 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34867892012-11-06 Taxanes for the Treatment of Metastatic Breast Cancer Gradishar, W.J. Review Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer (MBC). Since the introduction of Cremophor EL-paclitaxel to the clinic in the mid-1990s, a substantial amount of investigation has gone into subjects such as formulation, dose, schedule, and taxane resistance, allowing physicians greater flexibility in treating patients with MBC. This review will also examine how the shrinking pool of taxane-naive patients, a result of the expansion of taxanes into the neoadjuvant and adjuvant settings, will respond to taxane retreatment for metastatic disease. Taxane treatment seems likely to continue to play an important role in the treatment of MBC. Libertas Academica 2012-10-25 /pmc/articles/PMC3486789/ /pubmed/23133315 http://dx.doi.org/10.4137/BCBCR.S8205 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Gradishar, W.J. |
| spellingShingle |
Gradishar, W.J. Taxanes for the Treatment of Metastatic Breast Cancer |
| author_facet |
Gradishar, W.J. |
| author_sort |
Gradishar, W.J. |
| title |
Taxanes for the Treatment of Metastatic Breast Cancer |
| title_short |
Taxanes for the Treatment of Metastatic Breast Cancer |
| title_full |
Taxanes for the Treatment of Metastatic Breast Cancer |
| title_fullStr |
Taxanes for the Treatment of Metastatic Breast Cancer |
| title_full_unstemmed |
Taxanes for the Treatment of Metastatic Breast Cancer |
| title_sort |
taxanes for the treatment of metastatic breast cancer |
| description |
Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer (MBC). Since the introduction of Cremophor EL-paclitaxel to the clinic in the mid-1990s, a substantial amount of investigation has gone into subjects such as formulation, dose, schedule, and taxane resistance, allowing physicians greater flexibility in treating patients with MBC. This review will also examine how the shrinking pool of taxane-naive patients, a result of the expansion of taxanes into the neoadjuvant and adjuvant settings, will respond to taxane retreatment for metastatic disease. Taxane treatment seems likely to continue to play an important role in the treatment of MBC. |
| publisher |
Libertas Academica |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486789/ |
| _version_ |
1611920612167516160 |